Organisation paid for research Program year 2025 Source: CMS Open Payments

The Ima Group

Neither a doctor nor a teaching hospital

Research payments

$1,690,086

156 payments

Through program year 2025, The Ima Group is reported as receiving $1,690,086 in research payments, across 156 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $569,917 40
2024 Research $605,978 34
2023 Research $514,191 82

Breakdown

Who paid Research payments · program years 2023–2025
  1. E.R. Squibb & Sons, L.L.C. $1,091,772 28 payments
  2. GlaxoSmithKline, LLC. $557,581 103 payments
  3. Janssen Research & Development, LLC $40,733 25 payments
Studies the money was for Research payments · program years 2023–2025
  1. An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia $668,451 10 payments
  2. A Phase 3, Randomized, Placebo-Controlled, Observer-Blind, Multi-Count $391,807 45 payments
  3. A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) $194,178 4 payments
  4. A Phase 3, Open-Label, Randomized, Controlled, Multi Country Study to $87,983 17 payments
  5. Phase III OLE of KarXT in Adjuct Schiz (ARISE 2) - An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia $64,640 3 payments
  6. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease $56,058 2 payments
  7. A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation $40,733 25 payments
  8. A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia $40,400 2 payments
  9. A Phase 3, Randomized, Open-Label, Multi-Country Study to Evaluate the $33,471 9 payments
  10. An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia $32,607 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record